Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
live Bacillus licheniformis granules
- Development stage
- Unknown
- Lead developer
- Genoa Healthcare
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus viable particles (specifically referring to live *Bacillus licheniformis* granules, marketed under the brand name Zhengchangsheng) is a live biotherapeutic probiotic preparation containing live *Bacillus licheniformis* (strain CMCC63516). It is widely used in China to treat and prevent gastrointestinal disorders associated with gut microbiota dysbiosis, such as acute and chronic diarrhea, abdominal bloating, indigestion, and antibiotic-associated diarrhea (AAD). Upon oral administration, *Bacillus licheniformis* spores germinate in the intestinal tract, consuming oxygen to create an anaerobic environment that promotes the growth of beneficial anaerobic bacteria (such as *Bifidobacterium* and *Lactobacillus*) while antagonizing pathogenic bacteria. It also secretes antibacterial substances and active enzymes to help restore intestinal homeostasis and maintain mucosal barrier integrity.
- Brand names
- Zhengchangsheng
- Other names
- Bacillus viable particleslive Bacillus licheniformisBacillus licheniformis granules, live地衣芽孢杆菌活菌颗粒整肠生
Beyond the preview
Go deeper on live Bacillus licheniformis granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on live Bacillus licheniformis granules.